MX2023002928A - Encapsulacion de arn grande en nanoparticulas lipidicas. - Google Patents

Encapsulacion de arn grande en nanoparticulas lipidicas.

Info

Publication number
MX2023002928A
MX2023002928A MX2023002928A MX2023002928A MX2023002928A MX 2023002928 A MX2023002928 A MX 2023002928A MX 2023002928 A MX2023002928 A MX 2023002928A MX 2023002928 A MX2023002928 A MX 2023002928A MX 2023002928 A MX2023002928 A MX 2023002928A
Authority
MX
Mexico
Prior art keywords
sup
tube
rna
lipids
aqueous solution
Prior art date
Application number
MX2023002928A
Other languages
English (en)
Inventor
Priya Prakash Karmali
Yanjie Bao
Brenda Clemente
Original Assignee
Arcturus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Therapeutics Inc filed Critical Arcturus Therapeutics Inc
Publication of MX2023002928A publication Critical patent/MX2023002928A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Accessories For Mixers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para producir nanopartículas lipídicas con ARN encapsulado incluye hacer fluir una solución acuosa que comprende un ARN a través de un 1.er tubo que tiene un primer diámetro interno (ID); el ARN comprende de alrededor de 6000 a alrededor de 13 000 nucleótidos; hacer fluir una solución de etanol que comprende lípidos a través de un 2.o tubo que tiene un segundo diámetro interno (ID), a una velocidad de flujo de alrededor de 0.2 a alrededor de 1 veces con respecto a la solución acuosa a través del 1.er tubo, los lípidos comprenden un lípido catiónico, y mezclar la solución de etanol con la solución acuosa; el primer ID y el segundo ID y las velocidades de flujo a través del 1.er tubo y el 2.o tubo se seleccionan para producir una fuerza de cizallamiento suficientemente baja para conservar la integridad del ARN; la mezcla produce una solución de salida en el 1.er tubo que comprende un flujo turbulento del ARN y los lípidos entre el etanol, las nanopartículas lipídicas con ARN encapsulado tienen una estructura de bicapa.
MX2023002928A 2020-09-13 2021-09-13 Encapsulacion de arn grande en nanoparticulas lipidicas. MX2023002928A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077648P 2020-09-13 2020-09-13
PCT/US2021/050120 WO2022056413A1 (en) 2020-09-13 2021-09-13 Lipid nanoparticles encapsulation of large rna

Publications (1)

Publication Number Publication Date
MX2023002928A true MX2023002928A (es) 2023-06-12

Family

ID=80629902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002928A MX2023002928A (es) 2020-09-13 2021-09-13 Encapsulacion de arn grande en nanoparticulas lipidicas.

Country Status (10)

Country Link
US (1) US11938227B2 (es)
EP (1) EP4211247A1 (es)
JP (1) JP2023542643A (es)
KR (1) KR20230065281A (es)
CN (1) CN116490612A (es)
AU (1) AU2021340876A1 (es)
CA (1) CA3194951A1 (es)
IL (1) IL301253A (es)
MX (1) MX2023002928A (es)
WO (1) WO2022056413A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024055000A1 (en) * 2022-09-09 2024-03-14 The Trustees Of The University Of Pennsylvania Compositions and methods comprising lipid nanoparticle vaccines that elicit a modulated immune response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147089A0 (en) 1999-07-15 2002-08-14 Inex Pharmaceuticals Corp Methods of preparing lipid-encapsulated therapeutic agents
US20030040105A1 (en) * 1999-09-30 2003-02-27 Sklar Larry A. Microfluidic micromixer
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US9006417B2 (en) * 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
RU2647476C2 (ru) 2011-11-04 2018-03-15 Нитто Денко Корпорейшн Способ получения липидных наночастиц для доставки лекарственного средства
WO2014043625A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN105246586A (zh) 2013-03-14 2016-01-13 舒逸电子材料公司 用于合成纳米粒子的连续流动反应器
US10195291B2 (en) * 2013-09-24 2019-02-05 Alnylam Pharmaceuticals, Inc. Compositions and methods for the manufacture of lipid nanoparticles
EP3110401A4 (en) * 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CA2968060C (en) 2014-11-18 2023-06-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US20230149310A1 (en) * 2018-03-30 2023-05-18 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery

Also Published As

Publication number Publication date
JP2023542643A (ja) 2023-10-11
EP4211247A1 (en) 2023-07-19
CN116490612A (zh) 2023-07-25
WO2022056413A1 (en) 2022-03-17
KR20230065281A (ko) 2023-05-11
CA3194951A1 (en) 2022-03-17
US20220168234A1 (en) 2022-06-02
US11938227B2 (en) 2024-03-26
IL301253A (en) 2023-05-01
AU2021340876A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
Ren et al. Monodisperse alginate microcapsules with oil core generated from a microfluidic device
MX2023002928A (es) Encapsulacion de arn grande en nanoparticulas lipidicas.
CN103785311B (zh) 微纳米气泡发生装置
Martz et al. Microfluidic generation of acoustically active nanodroplets
CN103417463A (zh) 一种高渗透性乳化面膜
JP2007117853A (ja) 微細気泡発生装置
JP2016073939A (ja) 微細気泡発生装置
JPWO2018021182A1 (ja) 気泡生成装置、管状部材、気泡生成方法及び気泡生成装置の製造方法
CN206793438U (zh) 一种螺旋贯穿孔微细气泡产生装置
CN206676035U (zh) 一种球型多凸起微细气泡产生机构
CN206676257U (zh) 一种球型锥孔微细气泡产生机构
CN206676247U (zh) 一种微细气泡发生机构
CN109399813A (zh) 一种基于用于废水处理曝气的复合气液混合装置
CN206676258U (zh) 一种双球体微细气泡产生装置
JP7353381B2 (ja) 細胞内物質伝達のためのマイクロ流体システムおよび方法
Teh Development of droplet microfluidic platforms for the synthesis of monodisperse lipid vesicles and polymer particles
Zhang et al. X-ray Bubbles in Galaxy Clusters and their Role in Generating Internal Gravity Waves and Shaping Ha Filaments
Pandey Arrangement of Spherical Nanoparticles inside Nanoscale Liposomes
Hasegawa et al. Micro-bubble generation by using pipe with slits
Spangler et al. Arrangement of Spherical Nanoparticles on Nanoscale Liposomes
Sarkar et al. Jetting of a ultrasound contrast microbubble near a rigid wall
CN207019727U (zh) 一种多点取压皮托管静压取压阀
Torres Sánchez et al. Patterning of membrane adhesion under hydraulic stress
JP6408083B1 (ja) 気泡発生装置及び気泡発生方法
Kim et al. Hydraulic parallel design for microfluidic ultraviscous droplets